Background: The coexistence of functional thyroid nodules and Graves' disease (GD) is a rare condition known as Marine-Lenhart syndrome. Thyroid cancer has been described in several adults, but never in children, with Marine-Lenhart syndrome. This paper discusses the challenges in diagnosis and the unique management of this condition in children, in the context of extant literature. Content: In this case report, two adolescent female patients with Marine-Lenhart syndrome, aged 15 and 16 years, exhibited biochemical evidence of hyperthyroidism, and were found to have unilateral hyperfunctioning thyroid nodules via thyroid scintigraphy. Additionally, both patients showed elevated thyroid-stimulating immunoglobulins (TSI) and increased glandular activity, confirming background GD. Notably, one patient was also diagnosed with intranodular thyroid cancer upon preoperative examination. Both patients were treated via surgical resection. Summary and outlook: Diagnosis of Marine-Lenhart syndrome can be made in patients with functional thyroid nodules and increased glandular activity on thyroid scintigraphy. Standard doses of radioiodine ablation are not effective in the majority of patients and should be avoided due to the increased risk for thyroid cancer, making thyroidectomy the preferred treatment.
Introduction
The etiology of hyperthyroidism is extensive, ranging from increased endogenous production of circulating thyroid hormones to exogenous exposure. Of the former, diffuse thyroid hyperplasia, aka Graves' disease (GD), is by far the most common form of hyperthyroidism in children and adolescents [1] . In contrast, functional nodules are uncommon in this age group. These two conditions rarely co-exist and were first alluded to in an original paper published by Marine and Lenhart [2] , who lent their name to this syndrome.
The case series presented in this study describes two adolescent females diagnosed with Marine-Lenhart syndrome, one of whom had an additional finding of papillary thyroid cancer (PTC) within the hot nodule. While Marine-Lenhart syndrome has been reported once before in the pediatric literature [3] , this is the first reported case of a pediatric patient with coexisting Marine-Lenhart syndrome and thyroid cancer. This paper discusses the clinical history of the two patients, while highlighting the challenges in diagnosis and management of this syndrome in the context of extant literature.
Case study Case 1
A 15-year-old female presented with a 6-months' history of a slowly growing right-sided neck mass. Her pertinent symptoms were mild and included increased appetite, decreased sleep, night sweats and resting tremors. Thyroid function studies showed reduced levels of thyroid stimulating hormone (TSH) (<0.01 mIU/mL; reference range: 0.5-4.3 mIU/mL) and elevated free T4 (2.5 ng/dL) and total T3 (291 ng/dL) (reference ranges: 0.9-1.4 and 84-179 ng/dL, respectively). Her thyroid-stimulating immunoglobulin (TSI) level was 394% (reference range: <140%).
The patient's thyroid ultrasound showed asymmetric thyroid lobes (R lobe: 14.3 mL; L lobe: 8.3 mL). A dominant globular solid mass with internal blood flow and multiple calcifications, which measured 2.3 × 2.2 × 1.3 cm, was seen in the mid to lower third of the right thyroid lobe ( Figure 1A ). There was no evidence of cervical lymphadenopathy.
An I-123 scan showed elevated 4-and 24-h thyroid uptake values of 65% and 84%, respectively. In particular, there was increased uptake in the entire right lobe (60,459 counts or 4228 counts/mL of right lobe volume), with relative suppression of the left lobe (19,041 counts or 2294 counts/mL of left lobe volume). This asymmetric uptake was due to a right-sided hot nodule, seen as a focal enlargement in the lower third of the right lobe and which corresponded to the sonographic region of the right-sided mass ( Figure 1B) . Moreover, the lack of suppression of radioiodine uptake in the lobe contralateral to the hot nodule suggested a TSH-independent mechanism of extranodular activity.
The patient was started on methimazole and a betablocker, and was made euthyroid. Fine-needle aspiration cytology (FNAC) analysis of the right-sided nodule confirmed PTC, for which she underwent a total thyroidectomy. Surgical pathology analysis revealed a solid discrete area of pallor, approximately 1.0 cm in its widest dimension, encroaching the isthmus, with surrounding areas of less well-defined pallor, approximately 1.7 cm in diameter; the remainder of the parenchyma was red-brown. Microscopic examination revealed an unencapsulated tumor within the right thyroid lobe and features consistent with PTC, and there was clear evidence of angio and lymphatic invasion. The remainder of the gland showed extensive papillary hyperplasia. Metastatic neoplasm was found only in one lymph node within the central neck compartment. Post-operatively, her stimulated thyroglobulin level was 12.1 ng/mL with negative thyroglobulin antibodies. Subsequently, her I-123 whole body scan showed a prominent focus of uptake within the thyroid bed with two additional small foci of uptake inferior to this region, likely representing additional thyroid bed tissue. She received 98 milliCurie of I-131 radioactive iodine (RAI) and was maintained on levothyroxine therapy.
Case 2
A 16-year-old female presented to her pediatrician with non-specific neck pain. Aside from a history of oligomenorrhea she was otherwise healthy, with no acute symptoms. However, her neck exam was limited due to her obesity. Similar to patient #1, her thyroid function tests showed suppression of TSH (<0.01 mIU/mL), elevated free T4 (1.68 ng/dL) and total T3 (179 ng/dL) (reference ranges: 0.67-1.22 and 0.71-1.75 ng/dL, respectively), and a TSI of 215% (reference range: <140%). A neck ultrasound revealed a poorly defined hypervascular nodule within her left thyroid lobe, measuring 1.7 × 0.9 × 1.1 cm, which contained a tiny cyst (Figure 2A ). An I-123 scan showed increases in 4-and 24-h thyroid uptake of 38% and 50%, respectively. In particular, there was asymmetric glandular uptake at 24 h ( Figure 2B ), with proportional counts of 17,000 (72%) and 6600 (28%) in the left and right lobes, respectively, confirming a left-sided hot nodule. The patient was initially started on methimazole, and subsequent FNAC analysis of her thyroid nodule showed benign follicular cells. She underwent a total thyroidectomy for her hot nodule and coexisting GD. Her surgical pathology showed asymmetric thyroid lobes (L lobe: 14 mL; R lobe: 7.8 mL) with a left-sided focal irregular nodular area measuring 0.8 cm at its widest dimension. Microscopic examination of the left lobe showed a poorly circumscribed nodule composed of closely packed thyroid follicles separated by fibrous stroma and dystrophic calcification, without any evidence of thyroid cancer, which was surrounded by areas of diffuse hyperplasia. Meanwhile, the right lobe showed mildly irregular thyroid follicles with a few hyperplastic foci.
Ethics statement
Institutional review board (IRB) approval was not solicited as the study qualified under the category of exempt human subjects research, 45 CFR 46.101(b) (4): 'Research involving the collection or study of existing data, documents, records, pathological specimens, or diagnostic specimens, if these sources are publicly available or if the information is recorded by the investigator in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects'. The confidentiality and anonymity of all participating subjects was ensured at all times. Subject participation was completely voluntary and the patients did not come to any harm during the course of the study. The research was conducted in an independent and impartial manner.
Discussion and review
Marine-Lenhart syndrome was initially described in eight patients with exophthalmic goiter who were incidentally found to harbor functional thyroid nodules [2] . These nodules, although functional, were found to concentrate relatively low levels of iodine (between 12% and 40%), compared with the surrounding extranodular thyroid tissue. In 1972, Charkes [4] compared the functional nodules of the 10 Marine-Lenhart syndrome patients identified with those of patients with toxic multinodular goiter, aka Plummer's disease, with which MarineLenhart is often mistaken. Indeed, similar to those with Marine-Lenhart syndrome, patients with Plummer's disease present with a goiter and a functioning nodule. However, there are certain features that distinguish Plummer's disease from Marine-Lenhart syndrome: (1) absence of extra-thyroid manifestations; (2) absence of TSH-receptor stimulating antibodies; (3) presence of an activating somatic mutation of the TSH receptor; (4) TSH-independent regulation of the functioning thyroid nodule; and (5) TSH-dependent regulation of extranodular thyroid tissue. Applying these principles, Charkes established the following diagnostic criteria to define patients with Marine-Lenhart syndrome, which are based on the radioiodine uptake response of nodular and glandular thyroid tissue at baseline and after exogenous TSH administration: (1) radioiodine uptake showing increased glandular activity with one or more functional thyroid nodules; (2) failure of TSH to alter the scintigraphic appearance of the gland (not the nodule); (3) stimulation of overall radioiodine uptake by TSH; and (4) recovery of nodule function following TSH stimulation (i.e. nodule was TSH-dependent). In particular, criteria 1 and 2 must be met to rule out Plummer's disease, while criteria 3 and 4 are essential only in special circumstances. In the current study, while thyroid scintigraphy was not repeated in either patient following normalization of TSH levels, the increased extranodular iodine activity observed in these individuals during TSH suppression ruled out Plummer's disease. This, in addition to the elevated levels of TSH receptor-stimulating antibodies observed in each patient, confirmed the diagnosis of Marine-Lenhart syndrome.
The prevalence of Marine-Lenhart syndrome is difficult to estimate owing to its rarity. However, in his previous study, Charkes [4] studied 375 patients with GD, of which 2.7% (n = 10) had a functioning nodule. Similarly, Carnell and Valente [5] detected autonomous nodules in only 1% (n = 4) of the 468 GD patients studied.
While early studies primarily reported on low-functioning thyroid nodules, there have recently been increasing numbers of reports of GD patients with 'increased' nodular functionality [6] [7] [8] [9] [10] [11] , similar to the patients examined in this case series. This phenomenon led to the hypothesis that this association could comprise either a different clinical entity from, or more likely, an extension of Marine-Lenhart syndrome. Indeed, in 1997, Nishikawa et al. [10] provided the first report of a patient with a hot nodule and coexisting GD. The 44-year-old female patient was made euthyroid via administration of methimazole, which resulted in the recovery of endogenous TSH activity. She was later given suppressive doses of T3, which in turn decreased Tc-99 m nodular uptake, thereby confirming the nodular TSH dependence of Marine-Lenhart syndrome. The other frequently described Marine-Lenhart variant comprises patients with autonomous functioning thyroid nodules who were initially treated with RAI and eventually went on to develop GD [12] [13] [14] .
This case series is unique, not just because of the young age of the patients presenting with Marine-Lenhart syndrome, but also because one of these patients was found to harbor PTC within the toxic nodule. The effect of either GD or functional nodules on developing thyroid cancer has long been debated and is discussed in some detail below.
Thyroid cancer in GD
Thyroid nodularity is a common feature of GD, with an estimated prevalence of 25%-53% [15] [16] [17] . Moreover, 'palpable' thyroid nodules, although rare in GD patients (7%-16%) [15, 17] , are still approximately three times more common among these patients than in the general population living in non-endemic areas of iodine deficiency (4% prevalence rate) [18] . This is important because thyroid cancer is increasingly being found in patients with nodular GD. In fact, the average malignancy rate of palpable nodules in adults is approximately three times greater in patients with GD than in the general population (17% vs. 5%) [18, 19] . Overall, patients with GD are about 10 times more likely to have a malignant thyroid nodule than the general population. Staniforth et al. published a metaanalysis of 33 studies of surgically resected specimens and found the event rate of thyroid cancer in GD patients to be 0.07, which was much higher when compared with the thyroid cancer prevalence rate of 0.2% in the general population [20, 21] . Moreover, even among GD patients, the existing literature shows that the risk of developing thyroid cancer in nodular GD is almost five times greater than that in non-nodular GD, the majority which are PTC [20] . Given the above evidence, it is reasonable to conclude that GD (accentuated by the presence of thyroid nodularity) comprises a predisposing risk factor for the development of thyroid cancer. Moreover, the clinical course of thyroid cancer in nodular GD appears to be more aggressive than that in the general populace. Specifically, such cancers have a higher chance of being multifocal, are locally invasive with greater nodal and distant metastases, and are associated with less favorable outcomes, as evidenced by higher rates of persistent disease and cancer-related deaths [22] [23] [24] . In contrast, to the best of our knowledge, there have been no studies exclusively looking at the prevalence or behavior of thyroid cancers in children with GD.
Thyroid cancer in functional nodules
The impact of functional nodules on thyroid cancer is distinct from that seen in GD. To begin with, hot nodules are not commonly seen in children and adolescents; even solitary 'non-functional' thyroid nodules are rare among young people, with a prevalence of 0.22% and 1.8% in individuals 9-16 and 11-18 years old, respectively [25, 26] , compared to adults (4%-5%). Consistent with these studies, Hung [27] previously reported that only 13 of 92 patients aged 3-18 with a solitary thyroid nodule who underwent scintigraphy had a hot nodule, and none presented with a hot nodule and coexisting cancer. Similarly, Lafferty and Batch [28] found that among 32 children with nodular thyroid disease who underwent scintigraphy, only three had a hot nodule. Notably, however, one of these three patients also harbored thyroid cancer. Additionally, in recent years, there have been several other case reports of incidental detection of hot nodules in children [29] [30] [31] .
There are two published case series looking at hot nodules in children with coexisting thyroid cancer. In 1997, Croom et al. [32] reported that two of 12 patients with autonomously functioning thyroid nodules (ages 9-18 years) who underwent a thyroidectomy between 1968 and 1986 and had a hot nodule based on scintigraphy, also had differentiated thyroid cancer. Notably, this same group found that only 25% of a cohort of 61 pediatric patients diagnosed with hot nodules between 1956 and 1986 (including his own series) were clinically hyperthyroid, with the majority of these patients being asymptomatic and only confirmed via thyroid scintigraphy. Of the patients with hyperthyroidism, 40% showed elevated levels of T3 alone, while 30% exhibited elevated levels of both T3 and T4. Including his own two patients, there were a total of six out of 53 children and adolescents (11%) with reported thyroid cancer, four of whom had PTC. Similarly, Niedziela et al. [33] reported that nine of 31 children (aged 10-18 years) with hot nodules also had thyroid cancer within the hyperfunctioning nodule; PTC was seen in five of the nine patients, with the remainder having follicular thyroid cancer (FTC). Once again, only 45% of all children were clinically hyperthyroid at presentation, and T3-dependent thyrotoxicosis was seen in 32% of the children. The reported prevalence of thyroid cancer in hot nodules from the two studies was 10% and 30%, respectively (weighted average 7%).
The association between hot nodules and thyroid cancer has been studied more extensively in adults than in children. In a recent study, Mirfakhraee et al. [34] reviewed 14 case series and 77 individual patients with hyperfunctioning thyroid nodules and thyroid cancer. Intranodular carcinoma rates ranged from 0% to 12.5%, with a weighted average of 3.1%. An analysis of patient and nodular characteristics showed that the mean nodular size was 4.1 cm, which approximated benign hyperfunctioning nodules. Elevated levels of T3 and T4 were observed in 75% and 52% of these patients, respectively, and subclinical hyperthyroidism was observed in 13% of the patients. These findings mirrored the biochemical profile of non-malignant toxic nodules [35] [36] [37] , as well as that of the pediatric patients described above. Larger nodular size was associated with a higher incidence of frank hyperthyroidism. Notably, histopathological analyses revealed PTC, FTC, follicular variant of PTC, and Hurthle cell carcinoma in 57%, 36%, 18% and 9% of the malignant nodules, respectively (compared with 85% PTC, 10% FTC and 3% Hurthle cell carcinoma in the general population), indicating that while PTCs remain the predominant cancer type, FTCs are more likely to be seen in hot nodules than in nonfunctional nodules. Incidentally, 30% of the malignant nodules were incorrectly assigned as benign on pre-operative fine needle cytology.
Based on the available literature, the prevalence of thyroid cancer in hot nodules appears to be at least twofold higher in children than in adults (7% vs. 3%) [32] [33] [34] . While the mechanistic driving force behind the increased prevalence of thyroid cancer in pediatric hot nodules remains unclear, sequencing analyses of such nodules in children suggest that neither mutations in RAS and BRAF or rearrangements in PAX8/PPARG or RET/PTC, which are detectable in approximately two-thirds of adult patients with PTCs or FTCs, are likely to be responsible for this phenomenon [38] .
Thyroid cancer in Marine-Lenhart syndrome
The simultaneous occurrence of thyroid cancer in patients with Marine-Lenhart syndrome has only been reported in a handful of adult patients, and never in children, until now. In all, six such cases have been reported [37, [39] [40] [41] [42] [43] ; the mean age of presentation was 41 years, four of the six patients were males, and the average size of the largest nodular dimension was 1.6 cm. Of the six patients, five had PTC and one had FTC. One of the patients was also BRAF mutation-positive. Regional neck metastases were observed in two patients, but none showed evidence of distant metastasis.
Treatment strategies
The above evidence suggests that although hot nodules might be rarer in children than adults, the frequency of thyroid cancer in children with hot nodules is almost twofold greater than that in adults. Because of this, and due to the relative resistance of functioning nodules in patients with Marine-Lenhart syndrome to standard doses of RAI [4] , surgical resection is the recommended treatment of choice. While thyroidectomy is preferred over lobectomy due to background diffuse hyperthyroidism, lobectomy is acceptable in children with a solitary hot nodule. Again, RAI should be avoided in children with a solitary hot nodule due to a higher intranodular cancer risk, as well as an increased risk of developing secondary cancers from low-level whole body radiation exposure [44] . Consequently, preoperative FNAC is usually not warranted to rule out thyroid cancer in children with hot nodules (and subsequently in children with Marine-Lenhart syndrome) unless surgery is deferred because the patient is either asymptomatic or has subclinical hyperthyroidism [45] . Conversely, preoperative confirmation of nodular cancer may guide the clinician to evaluate and prepare for the possibility of extrathyroid extension and/or regional neck metastasis. If surgery is indeed deferred, the sonographic features of the nodule should be ascertained to determine the need for FNAC analysis.
This study had some limitations, mainly related to the lack of TSH response studies to evaluate for thyroid nodule autonomy. In the absence of such studies, one could postulate that the patients described here might display characteristics of coexisting Plummer's disease and GD, although this would be rare. Another possible explanation for the increased nodular radioiodine uptake seen here could be TSI induced nodular hyperactivity. However, Brown et al. [46] reported on a sub-group of patients with a single autonomously functioning thyroid nodule, but found that their representative TSI titers did not differ from those in a control group, making this etiology less likely. Eventually, the more likely explanation for the increased radioiodine uptake of the thyroid nodules described herein probably lies in their underlying structure. Charkes stated that the nodular architecture in his patients showed loosely packed follicles that were separated by stroma and other degenerative changes, which may account for their poor iodine uptake. This was thought to be related to the poor vascular supply of the nodule arising from the capsule. In contrast, the nodular pathology in one of our patients showed closely packed thyroid follicles, which may in part account for its increased radioiodine uptake.
Conclusions
A diagnosis of Marine-Lenhart syndrome, although rare, is made in patients with functioning thyroid nodules with coexisting GD. Although initially described in patients with poorly functioning nodules, this syndrome has now been expanded to include individuals with hyperfunctioning nodules. Currently, it is not the standard of practice to simultaneously evaluate for functional nodules and GD; however, suspicion should be raised in patients presenting with exophthalmic hyperthyroidism and a palpable thyroid nodule, or in cases where thyroid scintigraphy shows evidence of aforementioned features. A thyroidectomy is the preferred treatment of choice in pediatric patients with Marine-Lenhart syndrome due to the increased risk of developing thyroid cancer and poor response to standard doses of RAI.
